0.7615  -0.008 (-1.09%)		07-26 16:00
Open: 0.7612 High: 0.78 Volume: 85,962		Pre. Close: 0.7699 Low: 0.751 Market Cap: 14(M)

Short term
Mid term
Targets	6-month :	1.21	1-year :	1.51
Resists	First :	1.03	Second :	1.29
Pivot price	0.86
Supports	First :	0.61	Second :	0.5
MAs	MA(5) :	0.73	MA(20) :	0.91
	MA(100) :	1.86	MA(250) :	3.8
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	32.6	D(3) :	26.5
RSI	RSI(14): 34.8
52-week	High :	7.59	Low :	0.61

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BCTX ] has closed above bottom band by 28.4%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.78 - 0.78	0.78 - 0.79
Low:	0.74 - 0.75	0.75 - 0.75
Close:	0.75 - 0.76	0.76 - 0.77

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Thu, 18 Jul 2024
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer - StockTitan

Thu, 18 Jul 2024
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer - Markets Insider

Tue, 28 May 2024
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study - Yahoo Finance

Fri, 24 May 2024
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 - Yahoo Finance

Fri, 17 May 2024
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - Yahoo Finance

Wed, 15 May 2024
BriaCell stock falls on $5M stock offering (NASDAQ:BCTX) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	18 (M)
Shares Float	13 (M)
Held by Insiders	15.5 (%)
Held by Institutions	12 (%)
Shares Short	563 (K)
Shares Short P.Month	719 (K)

EPS	-0.38
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.38
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-122.8 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.93
Qtrly Earnings Growth	0 %
Operating Cash Flow	-31 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-2.06
PEG Ratio	0
Price to Book value	-2.06
Price to Sales	0
Price to Cash Flow	-0.45

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.